190141-99-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyrrolidinecarboxylic acid, 3-amino-4-hydroxy-, 1,1-dimethylethyl ester (9CI) is used as a pharmaceutical intermediate for the synthesis of various bioactive molecules and drug candidates. Its unique structure and functional groups enable the development of novel therapeutic agents with potential applications in treating various diseases and conditions.
Used in Peptide Synthesis:
In the field of peptide synthesis, 1-Pyrrolidinecarboxylic acid, 3-amino-4-hydroxy-, 1,1-dimethylethyl ester (9CI) serves as a key building block, allowing for the creation of diverse peptide sequences with specific biological activities. Its incorporation into peptide structures can enhance their stability, bioavailability, and therapeutic potential.
Used in Drug Development:
1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester(9CI) is utilized in drug development as a promising candidate for the discovery of new therapeutic agents. Its anti-cancer and anti-inflammatory properties make it an area of interest for researchers working on novel treatments for cancer, inflammatory diseases, and other conditions.
Used in Research and Development:
1-Pyrrolidinecarboxylic acid, 3-amino-4-hydroxy-, 1,1-dimethylethyl ester (9CI) is employed in research and development for the exploration of its potential applications in the medical and pharmaceutical industries. Its unique chemical properties and biological activities provide a foundation for the design and synthesis of innovative drug candidates and therapeutic agents.

Upstream product

• 203434-45-1 (±)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 190142-00-8 (3R,S)-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-(4R,S)-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 
• 1247884-24-7 tert-butyl 3-(3-cyanobenzamido)-4-hydroxypyrrolidine-1-carboxylate 
• 1215210-04-0 (3S,4S)-3-amino-4-hydroxypyrrolidine dihydrochloride 
• 1215485-03-2 3,4-diaminopyrrolidinyl-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Guanidine derivative and application thereof

The invention relates to a guanidine derivative serving as a VAP-1 inhibitor and application of the guanidine derivative, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be us

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in p

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceu

PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

2-6-diaminopurine precursors

The present invention relates to compounds of formula (IV): STR1 wherein Ra and Rb each represent a hydrogen atom or together form an alkylidene group.

Methyloxime-substituted aminopyrrolidine: A new surrogate for 7-basic group of quinolone

Novel fluoroquinolones containing oxime functionalized aminopyrrolidines have been synthesized. They were found to possess potent antibacterial activities both Gram-negative and Gram-positive organisms, including methicillin resistant Staphylococcus aureus (MRSA). Among these compounds, LB20277 (compound 12) showed the most favorable in vivo efficacy and pharmacokinetic profile in animals. Based on these promising results, LB20277 was selected as a candidate for further evaluation.